Exploring the Knowledge and Practices of Adverse Drug Reaction and Falsified Medicine Reporting Amongst the Community Pharmacists of India
Abstract
Background: Adverse drug reactions (ADRs) and falsified medicines (FMs) pose significant threat to patient safety and public health. Understanding the knowledge, experiences, and perspectives of community pharmacists in India regarding ADRs and FMs is crucial for effective intervention and prevention strategies.
Objective: This study aimed to assess the knowledge, experiences, and perspectives of community pharmacists in India regarding ADRs and FMs. It sought to gather information on pharmacists' familiarity with the threats posed by ADRs and FMs, their understanding of relevant legislation, their personal encounters with ADRs and FMs, and their views on the distribution of FMs and the adequacy of existing legislation.
Method: A survey was conducted among community pharmacists in India, and data were collected using a questionnaire. The survey included questions related to knowledge, experiences, and perspectives on ADRs and FMs. The responses were analysed to identify trends and key findings.
Results: The analysis revealed that a significant majority of pharmacists demonstrated a fundamental understanding of ADRs and FMs. However, a relatively low percentage reported encountering ADRs as well as FMs in their practice, with an equally low proportion reporting these incidents to the appropriate authorities Majority of pharmacists believed that they plan an important role in reporting of ADRs but only half of the pharmacists’ surveyed things that they plan an important role in tackling the issue of FMs.
Conclusion: The research highlights that community pharmacists in India have a good understanding of Pharmacovigilance and ADR reporting, although knowledge of Indian legislation needs improvement. Pharmacists demonstrate a positive attitude towards ADR reporting and promptly report encountered ADRs and FMs. Patient education, convenience of the reporting system, and strengthening FM legislation are areas that require attention. Major sources of FM distribution are online pharmacies and street hawkers. These findings contribute to enhancing pharmacovigilance practices and addressing FM distribution in India.
Downloads
References
2. Amale PN, Deshpande SA, Nakhate YD, Arsod NA. Pharmacovigilance Process in India: An overview. J Pharmacovigil. 2018;6(2):1-7.
3. Kalaiselvan V, Prasad T, Bisht A, Singh S, Singh GN. Adverse drug reactions reporting culture in Pharmacovigilance Programme of India. Indian J Med Res. 2014;140(4):563-564.
4. Ahmad A, Patel I, Balkrishnan R, Mohanta GP, Manna PK. An evaluation of knowledge, attitude, and practice of Indian pharmacists towards adverse drug reaction reporting: A pilot study. Perspect Clin Res. 2013;4(4):204-210.
5. Rajanand MG, Kumar V P, Yuvashakti S. Roles of Pharmacist in Pharmacovigilance: A Need of the Hour. J Pharmacovigil. 2016;04(06):1-2.
6. Pharmacovigilance Programme of India (PvPI). Performance Report 2015-16. Ghaziabad: Indian Pharmacopoeia Commission; 2015.p.1-?.
7. Pharmacovigilance Programme of India (PvPI). Performance Report 2015-16. Ghaziabad: Indian Pharmacopoeia Commission; 2016.p. 1-85.
8. Pharmacovigilance Programme of India (PvPI). Performance Report 2016-17. Ghaziabad: Indian Pharmacopoeia Commission; 2017.p.1-50.
9. Pharmacovigilance Programme of India (PvPI). Performance Report 2017-18. Ghaziabad: Indian Pharmacopoeia Commission; 2018.p.1-70.
10. Pharmacovigilance Programme of India (PvPI). Performance Report 2018-19. Ghaziabad: Indian Pharmacopoeia Commission; 2019.p.1-103.
11. Pharmacovigilance Programme of India (PvPI). Performance Report 2018-19. Ghaziabad: Indian Pharmacopoeia Commission; 2020.p.1-104.
12. Pharmacovigilance Programme of India (PvPI). Performance Report 2018-19. Ghaziabad: Indian Pharmacopoeia Commission; 2021.p.1-95.
13. Pharmacovigilance Programme of India (PvPI). Performance Report 2018-19. Ghaziabad: Indian Pharmacopoeia Commission; 2022.p.1-216.
14. Fernandes SD, Naryanan AV, Castelino LJ, Charyulu NR. A national approach to pharmacovigilance: The case of India as a growing hub of global clinical trials. Res Social Adm Pharm. 2019;15:109-113.
15. Ministry of Health and Family Welfare (Department of Health), Government of India. The Drugs and Cosmetics Act, 1940 (23 of 1940) and The Drugs and Cosmetics Rules, 1945 (As amended up to the 31st December, 2016) 2016 Dec.
16. Indian Pharmacopoeia Commission (IPC). Pharmacovigilance Guidance Document for Marketing Authorization Holders of Pharmaceutical Products. Ghaziabad: Indian Pharmacopoeia Commission, National Coordination Centres - Pharmacovigilance Programme of India; 2017.p.1-80.
17. Indian Pharmacopoeia Commission (IPC). Guidance Document for Spontaneous Adverse Drug Reaction Reporting. Ghaziabad: Indian Pharmacopoeia Commission, National Coordination Centres - Pharmacovigilance Programme of India; 2014.p.1-80.
18. Prakash J, Joshi K, Malik D, Mishra O, Sachan A, Kumar B, et al. “ADR PvPI” Android mobile app: Report adverse drug reaction at any time anywhere in India. Indian J Pharmacol. 2019;51(4):236.
19. Ferrario A, Orubu ESF, Adeyeye MC, Zaman MH, Wirtz VJ. The need for comprehensive and multidisciplinary training in substandard and falsified medicines for pharmacists. BMJ Glob Health. 2019;4(001681):1-3.
20. Khan AN, Khar RK. Current scenario of spurious and substandard medicines in India: A systematic review. Indian J Pharm Sci. 2015;77(1):2-7.
21. Press Information Bureau (PIB), Government of India. Health Ministry undertakes largest ever drug survey in the world for determining the quality of drugs [Internet]. PIB; 2020 Feb 10 [cited 2023 May 9]. Available from:
https://pib.gov.in/Pressreleaseshare.aspx?PRID=1483199
22. Ministry of Health & Family Welfare (MH&FW), Government of India. Reward Scheme for whistleblowers in the fight against the menace of spurious or fake drugs, cosmetics and medical devices, Central Drugs Standard Control Organization. 2009.p.1-9.
23. Lee KS, Yee SM, Zaidi STR, Patel RP, Yang Q, Al-Worafi YM, et al. Combating sale of counterfeit and falsified medicines online: A losing battle. Front Pharmacol. 2017;8:1-4.
24. Chambliss WG, Carroll WA, Kennedy D, Levine D, Moné MA, Ried LD, et al. Role of the Pharmacist in Preventing Distribution of Counterfeit Medications. J Am Pharm Assoc. 2012;52(2):195-199.
25. Hadi MA, Neoh CF, Zin RM, Elrggal ME, Cheema E. Pharmacovigilance: pharmacists' perspective on spontaneous adverse drug reaction reporting. Integr Pharm Res Pract. 2017;6:91-98.
26. Joubert M, Naidoo P. Knowledge, Perceptions and Practices of Pharmacovigilance amongst Community and Hospital Pharmacists in a Selected District of North West Province, South Africa. Health SA Gesondheid. 2016;21:238-244.
27. World Health Organization (WHO). Pharmacovigilance and Traditional and Complementary Medicine in South-East Asia: A Systemic Review. New Delhi: World Health Organization Regional Office for South-East Asia; 2019.p.1-26.
28. Salim M, Hussain N, Balasubramanian T, Lubab M, Nayana S, Hussain N, et al. The Current Perspective of Community Pharmacists towards Pharmacovigilance. J Pharmacovigil. 2015;03(05):1-7.
29. Sah R, Chandane R, Krishna, Manocha S, Kapur A. Knowledge, attitude and practice of pharmacovigilance among community pharmacists in Delhi, India. Int J Basic Clin Pharmacol. 2017;6(3):618-623.
30. Prakasham A, Nidamanuri A, Kumar S. Knowledge, perception and practice of pharmacovigilance among community pharmacists in South India. Pharmacy Pract. 2012;10(4):222-226.
31. Nagaraju K, Satheesh V, Shankar U, Banu R. A Study on Creating Awareness of Adverse Drug Reactions in Community Pharmacists in Bangalore. Indian J Pharm Pract. 2015;8(2):72-77.
32. Rahman S, Gupta V, Sukhlecha A, Khunte Y. Lifestyle drugs: Concept and impact on society. Indian J Pharm Sci. 2010;72(4):409.
33. Sample I. Fake drugs kill more than 250,000 children a year, doctors warn [Internet]. The Guardian; 2019 Mar 11 [cited cited 2023 May 9]. Available from:
https://www.theguardian.com/science/2019/mar/11/fake-drugs-kill-more-than-250000-children-a-year-doctors-warn
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Download link for COPYRIGHT FORM
